Abstract
Objective: The objective of the study is to systematically analyze and summarize research literature regarding health service use and costs of depressive symptoms in late life. Design: Relevant articles were identified by systematically searching the databases MEDLINE, Web of Science, PSYNDEXplus, PsycINFO, and Cochrane Library. Keywords were ‘depression’ or ‘depressive*’, and ‘cost’ or ‘economic burden’ or ‘utilization’ or ‘use’ and ‘old age’ or ‘elderly’. Studies based on representative samples of elderly individuals aged 55 years and older were included. Results: 55 studies were found, 34 studies determined health service utilization, 10 studies reported costs, and 11 studies reported both. Studies of health service utilization and costs showed homogeneously that depressive elderly individuals have an increased service use compared to non-depressive, and a one-third increase of outpatient, inpatient, and total healthcare costs of depressive individuals. The majority of studies reported antidepressant (AD) use between 20 and 45% by depressive individuals. Mean annual costs for AD ranged from 108 to 305 US$ PPP (purchasing power parities). Increased service use and costs are only to a small proportion related to depression treatment. Conclusions: Depressive symptoms in late life lead to a high economic burden for nations which is not explained by costs for depressive symptom treatment. Strategies for improvement of diagnostic validity and treatment success of depressive symptoms in late life may have an effect on economic burden for societies.
Keywords: Depression, depressive symptoms, health service use, utilization, economic burden, cost-of-illness, review, databases, elderly, antidepressant (AD)
Current Pharmaceutical Design
Title:Health Service Utilization and Costs of Depressive Symptoms in Late Life - A Systematic Review
Volume: 18 Issue: 36
Author(s): Melanie Luppa, Claudia Sikorski, Tom Motzek, Alexander Konnopka, Hans-Helmut Konig and Steffi G. Riedel-Heller
Affiliation:
Keywords: Depression, depressive symptoms, health service use, utilization, economic burden, cost-of-illness, review, databases, elderly, antidepressant (AD)
Abstract: Objective: The objective of the study is to systematically analyze and summarize research literature regarding health service use and costs of depressive symptoms in late life. Design: Relevant articles were identified by systematically searching the databases MEDLINE, Web of Science, PSYNDEXplus, PsycINFO, and Cochrane Library. Keywords were ‘depression’ or ‘depressive*’, and ‘cost’ or ‘economic burden’ or ‘utilization’ or ‘use’ and ‘old age’ or ‘elderly’. Studies based on representative samples of elderly individuals aged 55 years and older were included. Results: 55 studies were found, 34 studies determined health service utilization, 10 studies reported costs, and 11 studies reported both. Studies of health service utilization and costs showed homogeneously that depressive elderly individuals have an increased service use compared to non-depressive, and a one-third increase of outpatient, inpatient, and total healthcare costs of depressive individuals. The majority of studies reported antidepressant (AD) use between 20 and 45% by depressive individuals. Mean annual costs for AD ranged from 108 to 305 US$ PPP (purchasing power parities). Increased service use and costs are only to a small proportion related to depression treatment. Conclusions: Depressive symptoms in late life lead to a high economic burden for nations which is not explained by costs for depressive symptom treatment. Strategies for improvement of diagnostic validity and treatment success of depressive symptoms in late life may have an effect on economic burden for societies.
Export Options
About this article
Cite this article as:
Luppa Melanie, Sikorski Claudia, Motzek Tom, Konnopka Alexander, Konig Hans-Helmut and G. Riedel-Heller Steffi, Health Service Utilization and Costs of Depressive Symptoms in Late Life - A Systematic Review, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523572
DOI https://dx.doi.org/10.2174/138161212803523572 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in High-Field Magnetic Resonance Spectroscopy in Alzheimer’s Disease
Current Alzheimer Research Non-Cholinergic Pharmacotherapy Approaches to Alzheimers Disease: The Use of Non-Steroidal Anti-Inflammatory Drugs
CNS & Neurological Disorders - Drug Targets Editorial: Pain in Dementia: A Distressing Combination of Several Factors
Current Alzheimer Research Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II
Current Hypertension Reviews Structural and Functional MRI in Mild Cognitive Impairment
Current Alzheimer Research Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Anti-Alzheimer’s Materials Isolated from Marine Bio-resources: A Review
Current Alzheimer Research Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Experimental Approaches to Tse Prevention Via Inhibition of Prion Formation
Protein & Peptide Letters Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Optimal Treatment of Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Effect of Brain-Derived Neurotrophic Factor (BDNF) Gene Variants on the Therapeutic Response and the Risk for Mood Disorders
Current Pharmacogenomics and Personalized Medicine Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics
CNS & Neurological Disorders - Drug Targets Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews